tiprankstipranks
Hims & Hers Health (HIMS)
NYSE:HIMS
US Market
HIMS
Hims & Hers Health
RESEARCH TOOLSreports

Hims & Hers Health (HIMS) Stock Forecast & Price Target

9,273 Followers
See the Price Targets and Ratings of:

HIMS Analyst Ratings

Moderate Buy
14Ratings
Moderate Buy
4 Buy
10 Hold
0 Sell
Based on 14 analysts giving stock ratings to
Hims
& Hers Health
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

HIMS Stock 12 Month Forecast

Average Price Target

$26.55
▲(38.71% Upside)
Based on 14 Wall Street analysts offering 12 month price targets for Hims & Hers Health in the last 3 months. The average price target is $26.55 with a high forecast of $35.00 and a low forecast of $21.00. The average price target represents a 38.71% change from the last price of $19.14.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"$15","27":"$27","39":"$39","51":"$51","63":"$63"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26.55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$26.55</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$21.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,27,39,51,63],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.84,21.006153846153847,22.17230769230769,23.338461538461537,24.504615384615384,25.67076923076923,26.836923076923078,28.00307692307692,29.16923076923077,30.335384615384616,31.50153846153846,32.667692307692306,33.83384615384615,{"y":35,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.84,20.356153846153845,20.872307692307693,21.388461538461538,21.904615384615383,22.42076923076923,22.936923076923076,23.453076923076924,23.96923076923077,24.485384615384618,25.001538461538463,25.517692307692307,26.033846153846156,{"y":26.55,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.84,19.92923076923077,20.018461538461537,20.107692307692307,20.196923076923078,20.286153846153844,20.375384615384615,20.464615384615385,20.553846153846155,20.643076923076922,20.732307692307693,20.821538461538463,20.91076923076923,{"y":21,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":31.05,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":36.16,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":56.77,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 17</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":47.96,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":62.55,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":41.53,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":56.31,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":45.46,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 18</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":37.51,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 15</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":32.47,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.44,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":16.48,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.84,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$35.00Average Price Target$26.55Lowest Price Target$21.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on HIMS
Allen Lutz
Bank of America Securities
Bank of America Securities
$23
Hold
20.17%
Upside
Reiterated
04/02/26
Analysts' Top Healthcare Picks: AbbVie (ABBV), Takeda Pharmaceutical Co (TKPHF)
TD Cowen Analyst forecast on HIMS
Jonna Kim
TD Cowen
TD Cowen
$25→$23
Hold
20.17%
Upside
Reiterated
03/27/26
Hims & Hers price target lowered to $23 from $25 at TD CowenHims & Hers price target lowered to $23 from $25 at TD Cowen
Canaccord Genuity Analyst forecast on HIMS
Maria Ripps
Canaccord Genuity
Canaccord Genuity
$30
Buy
56.74%
Upside
Reiterated
03/26/26
Buy Rating on Hims & Hers: Undervalued Growth Leveraging Novo Nordisk GLP-1 Partnership and Scale Advantages
Truist Financial Analyst forecast on HIMS
Jailendra Singh
Truist Financial
Truist Financial
―
Hold
―
Reiterated
03/20/26
Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (NASDAQ: ELDN), Hims & Hers Health (NYSE: HIMS) and Solid Biosciences (NASDAQ: SLDB)
Leerink Partners Analyst forecast on HIMS
Michael Cherny
Leerink Partners
Leerink Partners
$17.5→$25
Hold
30.62%
Upside
Reiterated
03/16/26
Hims & Hers price target raised to $25 from $17.50 at LeerinkHims & Hers price target raised to $25 from $17.50 at Leerink
Barclays Analyst forecast on HIMS
Glen Santangelo
Barclays
Barclays
$25→$29
Buy
51.52%
Upside
Assigned
03/11/26
Analysts Offer Insights on Healthcare Companies: Hims & Hers Health (NYSE: HIMS) and Medtronic (NYSE: MDT)
Deutsche Bank Analyst forecast on HIMS
George Hill
Deutsche Bank
Deutsche Bank
$25→$28
Hold
46.29%
Upside
Reiterated
03/10/26
Hims & Hers price target raised to $28 from $25 at Deutsche BankHims & Hers price target raised to $28 from $25 at Deutsche Bank
Citi Analyst forecast on HIMS
Daniel Grosslight
Citi
Citi
$13.25→$24
Hold
25.39%
Upside
Upgraded
03/10/26
Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (NASDAQ: DNTH), Myomo (NYSE MKT: MYO) and Hims & Hers Health (NYSE: HIMS)
Nephron Analyst forecast on HIMS
Unknown Analyst
Nephron
Not Ranked
Nephron
$35
Buy
82.86%
Upside
Upgraded
03/09/26
Hims & Hers upgraded to Buy from Hold at Nephron ResearchHims & Hers upgraded to Buy from Hold at Nephron Research
Morgan Stanley Analyst forecast on HIMS
Craig Hettenbach
Morgan Stanley
Morgan Stanley
$21
Hold
9.72%
Upside
Reiterated
03/09/26
Analysts Offer Insights on Healthcare Companies: Exelixis (NASDAQ: EXEL), Hims & Hers Health (NYSE: HIMS) and Regeneron (NASDAQ: REGN)
Needham Analyst forecast on HIMS
Ryan MacDonald
Needham
Needham
$30
Buy
56.74%
Upside
Upgraded
03/09/26
Analysts Offer Insights on Healthcare Companies: NovaBridge Biosciences (NASDAQ: NBP) and Hims & Hers Health (NYSE: HIMS)
BTIG Analyst forecast on HIMS
David Larsen
BTIG
BTIG
―
Hold
―
Reiterated
03/05/26
Analysts Conflicted on These Healthcare Names: Hims & Hers Health (NYSE: HIMS) and ACADIA Pharmaceuticals (NASDAQ: ACAD)
Evercore ISI Analyst forecast on HIMS
Mark Mahaney
Evercore ISI
Evercore ISI
$33→$24
Hold
25.39%
Upside
Reiterated
02/24/26
Hims & Hers price target lowered to $24 from $33 at Evercore ISIHims & Hers price target lowered to $24 from $33 at Evercore ISI
KeyBanc Analyst forecast on HIMS
Justin Patterson
KeyBanc
KeyBanc
―
Hold
―
Reiterated
02/24/26
Analysts Offer Insights on Healthcare Companies: Brookdale Senior Living (NYSE: BKD), Kyntra Bio (NASDAQ: KYNB) and Hims & Hers Health (NYSE: HIMS)
Mizuho Securities Analyst forecast on HIMS
Unknown Analyst
Mizuho Securities
Not Ranked
Mizuho Securities
$30
Sell
56.74%
Upside
Reiterated
11/18/25
Mizuho Securities Reaffirms Their Sell Rating on Hims & Hers Health (HIMS)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on HIMS
Allen Lutz
Bank of America Securities
Bank of America Securities
$23
Hold
20.17%
Upside
Reiterated
04/02/26
Analysts' Top Healthcare Picks: AbbVie (ABBV), Takeda Pharmaceutical Co (TKPHF)
TD Cowen Analyst forecast on HIMS
Jonna Kim
TD Cowen
TD Cowen
$25→$23
Hold
20.17%
Upside
Reiterated
03/27/26
Hims & Hers price target lowered to $23 from $25 at TD CowenHims & Hers price target lowered to $23 from $25 at TD Cowen
Canaccord Genuity Analyst forecast on HIMS
Maria Ripps
Canaccord Genuity
Canaccord Genuity
$30
Buy
56.74%
Upside
Reiterated
03/26/26
Buy Rating on Hims & Hers: Undervalued Growth Leveraging Novo Nordisk GLP-1 Partnership and Scale Advantages
Truist Financial Analyst forecast on HIMS
Jailendra Singh
Truist Financial
Truist Financial
―
Hold
―
Reiterated
03/20/26
Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (NASDAQ: ELDN), Hims & Hers Health (NYSE: HIMS) and Solid Biosciences (NASDAQ: SLDB)
Leerink Partners Analyst forecast on HIMS
Michael Cherny
Leerink Partners
Leerink Partners
$17.5→$25
Hold
30.62%
Upside
Reiterated
03/16/26
Hims & Hers price target raised to $25 from $17.50 at LeerinkHims & Hers price target raised to $25 from $17.50 at Leerink
Barclays Analyst forecast on HIMS
Glen Santangelo
Barclays
Barclays
$25→$29
Buy
51.52%
Upside
Assigned
03/11/26
Analysts Offer Insights on Healthcare Companies: Hims & Hers Health (NYSE: HIMS) and Medtronic (NYSE: MDT)
Deutsche Bank Analyst forecast on HIMS
George Hill
Deutsche Bank
Deutsche Bank
$25→$28
Hold
46.29%
Upside
Reiterated
03/10/26
Hims & Hers price target raised to $28 from $25 at Deutsche BankHims & Hers price target raised to $28 from $25 at Deutsche Bank
Citi Analyst forecast on HIMS
Daniel Grosslight
Citi
Citi
$13.25→$24
Hold
25.39%
Upside
Upgraded
03/10/26
Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (NASDAQ: DNTH), Myomo (NYSE MKT: MYO) and Hims & Hers Health (NYSE: HIMS)
Nephron Analyst forecast on HIMS
Unknown Analyst
Nephron
Not Ranked
Nephron
$35
Buy
82.86%
Upside
Upgraded
03/09/26
Hims & Hers upgraded to Buy from Hold at Nephron ResearchHims & Hers upgraded to Buy from Hold at Nephron Research
Morgan Stanley Analyst forecast on HIMS
Craig Hettenbach
Morgan Stanley
Morgan Stanley
$21
Hold
9.72%
Upside
Reiterated
03/09/26
Analysts Offer Insights on Healthcare Companies: Exelixis (NASDAQ: EXEL), Hims & Hers Health (NYSE: HIMS) and Regeneron (NASDAQ: REGN)
Needham Analyst forecast on HIMS
Ryan MacDonald
Needham
Needham
$30
Buy
56.74%
Upside
Upgraded
03/09/26
Analysts Offer Insights on Healthcare Companies: NovaBridge Biosciences (NASDAQ: NBP) and Hims & Hers Health (NYSE: HIMS)
BTIG Analyst forecast on HIMS
David Larsen
BTIG
BTIG
―
Hold
―
Reiterated
03/05/26
Analysts Conflicted on These Healthcare Names: Hims & Hers Health (NYSE: HIMS) and ACADIA Pharmaceuticals (NASDAQ: ACAD)
Evercore ISI Analyst forecast on HIMS
Mark Mahaney
Evercore ISI
Evercore ISI
$33→$24
Hold
25.39%
Upside
Reiterated
02/24/26
Hims & Hers price target lowered to $24 from $33 at Evercore ISIHims & Hers price target lowered to $24 from $33 at Evercore ISI
KeyBanc Analyst forecast on HIMS
Justin Patterson
KeyBanc
KeyBanc
―
Hold
―
Reiterated
02/24/26
Analysts Offer Insights on Healthcare Companies: Brookdale Senior Living (NYSE: BKD), Kyntra Bio (NASDAQ: KYNB) and Hims & Hers Health (NYSE: HIMS)
Mizuho Securities Analyst forecast on HIMS
Unknown Analyst
Mizuho Securities
Not Ranked
Mizuho Securities
$30
Sell
56.74%
Upside
Reiterated
11/18/25
Mizuho Securities Reaffirms Their Sell Rating on Hims & Hers Health (HIMS)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Hims & Hers Health

3 Months
xxx
Success Rate
9/12 ratings generated profit
75%
Average Return
+26.96%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +26.96% per trade.
1 Year
Glen SantangeloBarclays
Success Rate
7/9 ratings generated profit
78%
Average Return
+35.73%
Copying Glen Santangelo's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +35.73% per trade.
2 Years
xxx
Success Rate
7/9 ratings generated profit
78%
Average Return
+37.00%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 77.78% of your transactions generating a profit, with an average return of +37.00% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HIMS Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
1
1
6
7
7
Buy
1
1
1
4
4
Hold
13
12
20
31
29
Sell
13
13
12
9
6
Strong Sell
2
0
0
0
0
total
30
27
39
51
46
In the current month, HIMS has received 11 Buy Ratings, 29 Hold Ratings, and 6 Sell Ratings. HIMS average Analyst price target in the past 3 months is 26.55.
Each month's total comprises the sum of three months' worth of ratings.

HIMS Financial Forecast

HIMS Earnings Forecast

Next quarter’s earnings estimate for HIMS is <$0.01 with a range of -$0.21 to $0.15. The previous quarter’s EPS was $0.08. HIMS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year HIMS has Performed in-line its overall industry.
Next quarter’s earnings estimate for HIMS is <$0.01 with a range of -$0.21 to $0.15. The previous quarter’s EPS was $0.08. HIMS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year HIMS has Performed in-line its overall industry.

HIMS Sales Forecast

Next quarter’s sales forecast for HIMS is $616.50M with a range of $608.37M to $632.50M. The previous quarter’s sales results were $617.82M. HIMS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year HIMS has Performed in-line its overall industry.
Next quarter’s sales forecast for HIMS is $616.50M with a range of $608.37M to $632.50M. The previous quarter’s sales results were $617.82M. HIMS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year HIMS has Performed in-line its overall industry.

HIMS Stock Forecast FAQ

What is HIMS’s average 12-month price target, according to analysts?
Based on analyst ratings, Hims & Hers Health’s 12-month average price target is 26.55.
    What is HIMS’s upside potential, based on the analysts’ average price target?
    Hims & Hers Health has 38.71% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is HIMS a Buy, Sell or Hold?
          Hims & Hers Health has a consensus rating of Moderate Buy which is based on 4 buy ratings, 10 hold ratings and 0 sell ratings.
            What is Hims & Hers Health’s price target?
            The average price target for Hims & Hers Health is 26.55. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $35.00 ,the lowest forecast is $21.00. The average price target represents 38.71% Increase from the current price of $19.14.
              What do analysts say about Hims & Hers Health?
              Hims & Hers Health’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Streets Analysts.
                How can I buy shares of HIMS?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.